Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies

Daniela C. Salles, Thiago Vidotto, Farzana A. Faisal, Jeffrey J. Tosoian, Liana B. Guedes, Andrea Muranyi, Isaac Bai, Shalini Singh, Dongyao Yan, Kandavel Shanmugam, Tamara L. Lotan

Research output: Contribution to journalArticlepeer-review


This study leveraged a gene-protein assay to assess MYC and PTEN status at prostate cancer biopsy and examined the association with adverse outcomes after surgery. MYC gain and PTEN loss were simultaneously assessed by chromogenic in situ hybridization and immunohistochemistry, respectively, using 277 Grade Group 2 needle biopsies that were followed by prostatectomy. The maximal size of cribriform Gleason pattern 4 carcinoma (CRIB), the presence of intraductal carcinoma (IDC), and percentage of Gleason pattern 4 carcinoma at biopsy were also annotated. MYC gain or PTEN loss was present in 19% and 18% of biopsies, respectively, whereas both alterations were present in 9% of biopsies. Tumors with one or both alterations were significantly more likely to have non–organ-confined disease (NOCD) at radical prostatectomy. In logistic regression models, including clinical stage, tumor volume on biopsy, and presence of CRIB/IDC, cases with MYC gain and PTEN loss remained at higher risk for NOCD (odds ratio, 6.23; 95% CI, 1.74–24.55; P = 0.005). The area under the curve for a baseline model using CAPRA variables (age, prostate-specific antigen, percentage of core involvement, clinical stage) was increased from 0.68 to 0.69 with inclusion of CRIB/IDC status and to 0.75 with MYC/PTEN status. Dual MYC/PTEN status can be assessed in a single slide and is independently associated with increased risk of NOCD for Grade Group 2 biopsies.

Original languageEnglish (US)
Pages (from-to)1030-1041
Number of pages12
JournalJournal of Molecular Diagnostics
Issue number8
StatePublished - Aug 2021

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine


Dive into the research topics of 'Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies'. Together they form a unique fingerprint.

Cite this